Director, Supply Chain & External Manufacturing at Tessera Therapeutics

Somerville, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

BS in Engineering or Life Science Discipline with 15 years related experience or Masters with 13 years related experience or PhD with 10 years of related experience
Proven leadership in all areas of Supply Chain and CMO relationship management
Broad experience in supply chain processes, methodologies, and technologies
Experience and ability to draft, revise, review, and negotiate complex CMO contract terms
Strong financial acumen with experience managing budget and P&L
Exceptional written and verbal communication skills
Proven ability for strategic thinking in a complex business environment
Preferred Qualifications
Certifications in clinical supply chain management, project management
Knowledge of gene therapy regulatory guidance
Experience working in a gene therapy supply chain role or with gene therapy modalities
Experience building clinical supply chain capabilities in US and EU

Responsibilities

Designing, building, and implementing phase appropriate supply chain and external manufacturing network strategies that ensure timely growth of capabilities and continuous supply of critical materials
Driving the identification, contracting, relationship management, and performance of critical GMP supply chain and CMO partners
Engaging in portfolio and program planning to ensure processes and capabilities are established to meet company needs and that critical materials are delivered on time
Working collaboratively with Process Development, Manufacturing, Quality, Regulatory, Legal, Procurement, Finance, and other key stakeholders
Establishing and leading cross-functional teams responsible for ensuring successful project execution with CMO partners
Providing financial oversight and leading/supporting overall business improvement opportunities with External Parties
Being responsible for supply chain and external manufacturing budgeting and providing strategic input into long-range planning processes

Skills

Supply Chain Management

External Manufacturing

CMO Management

GMP

Contract Negotiation

Portfolio Planning

Cross-Functional Leadership

Budgeting

Strategic Planning

Tessera Therapeutics

Develops gene editing technology for genetic medicine

About Tessera Therapeutics

Tessera Therapeutics focuses on genetic medicine, utilizing a technology called Gene Writing to make precise changes to the human genome. This technology allows for permanent alterations to genetic material in any cell, which can potentially cure diseases at their source. Tessera's Gene Writing platform can perform both small and large genetic modifications, making it applicable to a wide range of genetic disorders. The company primarily serves research institutions, pharmaceutical companies, and healthcare providers looking to develop new treatments for genetic diseases. Unlike its competitors, Tessera Therapeutics emphasizes the versatility of its technology and its ability to address previously untreatable conditions. The company's goal is to advance the development of its Gene Writing platform to ultimately cure diseases by rewriting the genetic code.

Cambridge, MassachusettsHeadquarters

2018Year Founded

$518.2MTotal Funding

SERIES_CCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Tuition Reimbursement

Risks

Competition from CRISPR-based technologies may challenge Tessera's market position.

High development costs could delay Gene Writing technology's market entry.

Regulatory hurdles may slow approval and adoption of genetic therapies.

Differentiation

Tessera Therapeutics pioneers Gene Writing, a novel approach in genetic medicine.

Their technology allows precise genome alterations, surpassing traditional gene editing methods.

Tessera's platform targets a wide range of genetic disorders with versatile applications.

Upsides

Partnership with Gates Foundation boosts development of sickle cell disease treatment.

$300 million Series C funding in 2022 supports platform advancement and commercialization.

Located in Boston, Tessera benefits from a thriving biotech ecosystem.

Land your dream remote job 3x faster with AI

Try Jobo Free